NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
29.64
-0.91 (-2.98%)
At close: Jul 24, 2026, 4:00 PM EDT
30.09
+0.45 (1.52%)
After-hours: Jul 24, 2026, 7:58 PM EDT
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $3.04M in the quarter ending March 31, 2026, with 2.08% growth. This brings the company's revenue in the last twelve months to $22.57M, down -52.13% year-over-year. In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%.
Revenue (ttm)
$22.57M
Revenue Growth
-52.13%
P/S Ratio
153.56
Revenue / Employee
$225,650
Employees
100
Market Cap
3.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.50M | -23.06M | -50.61% |
| Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
| Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
| Dec 31, 2022 | 102.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Arcutis Biotherapeutics | 415.62M |
| Arcus Biosciences | 236.00M |
| IDEAYA Biosciences | 225.27M |
| Tango Therapeutics | 56.99M |
| Alumis | 8.40M |
NAMS News
- 13 hours ago - NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco - TheFly
- 16 hours ago - NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - GlobeNewsWire
- 4 days ago - NewAmsterdam Pharma initiated with an Outperform at BMO Capital - TheFly
- 22 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - GlobeNewsWire
- 24 days ago - NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital - TheFly
- 6 weeks ago - NewAmsterdam Pharma Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts